Policy, Pricing and Power Shifts: How EU, UK and Global Policy Changes Are Reshaping Market Access
Author: Malcolm Boyd, Senior Consultant, Policy & Public Affairs At the World EPA Congress 2026 in Amsterdam, I had the […]
Insights
Aut-idem Meets Biologics: Mandatory Substitution as a Game Changer in Germany
Author: Tobias Schüning, Consultant, Market Access Aut‑idem Meets Biologics: Mandatory Substitution as a Game Changer in Germany (Medicines Directive (AM‑RL)
Nick Sullivan Appointed New Chief Executive Officer of Kintiga
A recognised leader in Market Access and HEOR, Nick Sullivan brings more than two decades of technical, operational, and business building expertise With this appointment, Kintiga is strengthening its leadership to deliver
The New Architecture of U.S. Drug Pricing: A Guide for the 2026 Landscape
The drug pricing conversation has shifted. While many are still focused on the Inflation Reduction Act (IRA), a series of
The EU Pharmaceutical Package: Political Agreement and Strategic Consequences
Author: Florian Stieglitz, Consultant, Market Access From Proposal to Political Agreement Nearly three years after the European Commission presented its proposal
Structural Shifts in German Pharmaceutical Regulation: Policy Alignment, Data Integration, and Evolving Cost Pressure
Author: Florian Stieglitz, Consultant, Market Access The German pharmaceutical policy landscape is currently changing in numerous ways. Developments originating from
AI in Health Authorities & EU HTA: From Pilot to Strategic Imperative
Author: Florian Stieglitz, Consultant, Market Access Artificial intelligence (AI) is reshaping how regulators, payers, and manufacturers interact with evidence. The Joint
Reimbursement Is Assured, Value Is Negotiated
Reimbursement Is Assured, Value Is Negotiated Author: Tobias Schüning, Consultant Did you know, that when a new drug receives EMA
Poster Presentation: Increased trends of self-optimised submissions to NICE (HTA 199)
Author: Albert Kwarciak Tuesday 11th Nov 2025 Poster Presentation: 10:30 – 13:30 Discussion Period: 12:30 – 13:30 OBJECTIVES A recent
Poster Presentation: Individual Therapy or no therapy at all? Impact of patient individual therapies as ACT in the German AMNOG process (HTA 200)
Authors: Joey Rehkopf, Malte Glüsen, Sebastian Vinzens, Ingo Hantke, Matthias P. Schönermark Tuesday 11th Nov 2025 Poster Presentation: 10:30 –
